Top

Published in:

01-12-2020 | Bisphosphonate | Original Article

Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

Authors: Yi Ting Chau, Nazrul Nashi, Lawrence Siu-Chun Law, Raymond Kai Heng Goh, Selena Xueli Choo, Santhosh Kumar Seetharaman

Published in: Archives of Osteoporosis | Issue 1/2020

Abstract

Summary

Undertreatment of osteoporosis after hip fracture increases the risk of death, disability, recurrent osteoporotic fractures, and financial burden. Only half were compliant with osteoporosis medications. Elderly patients were less persistent and compliant to treatment. Denosumab was associated with a higher proportion of days covered by osteoporosis medications than oral bisphosphonates.

Purpose

The aim of this study was to identify factors that contributed to the initiation of osteoporosis medications following hip fracture as well as the compliance and persistence to osteoporosis medications.

Methods

Clinical data of 532 patients older than 50 years old admitted for surgical fixation of hip fractures were reviewed. Three hundred forty-seven had sufficient data for analysis after excluding patients with non-fragility fractures. Prescription for any osteoporosis medication in the year following hip fracture as well as compliance to treatment was evaluated.

Results

Only 40.3% of patients were prescribed with osteoporosis medication within 1 year post-hip fracture. Females (p = 0.020) performing dual-energy x-ray absorptiometry scan (p < 0.001) and 25 hydroxyvitamin D levels testing post-hip fracture (p < 0.027) were independent determinants of increased likelihood of being prescribed with osteoporosis medication. Patients with proportion of days covered (PDC) ≥ 0.8 (or 80% of days covered in a year) were defined as compliant. Overall, only 49.7% of the patients were compliant with osteoporosis medications. Elderly patients aged 70–79 years (p = 0.002) and males (p = 0.017) were less persistent with osteoporosis treatment when compared with patients aged < 69 years and females. The compliance was poorer in patients aged 70–79 years (p = 0.026) as compared with those under 69 years of age. Statistically significant difference (p = 0.032) was observed between mean PDC of oral bisphosphonates (0.66) and denosumab (0.83). Only 39.3% of patients were persistent with treatment at 1 year.

Conclusion

Our findings demonstrate the urgent need to increase awareness through a structured protocol of osteoporosis treatment. A multi-disciplinary Fracture Liaison Service should be set up to ensure compliance to osteoporosis medication post-hip fracture.

Available only for authorised users

Foundation IO (2018) IOF compendium of osteoporosis. [cited 2018 Apr 10]. Available from: https://www.iofbonehealth.org/compendium-of-osteoporosis

Ng C, Lau T, Ko Y (2017) Cost of osteoporotic fractures in Singapore. Value Health Reg Issues 12:27–35PubMed

Foundation IO (2009) The Asian audit: epidemiology, costs and burden of osteoporosis in Asia 2009. [cited 2018 Apr 10]. Available from: https://www.iofbonehealth.org/sites/default/files/PDFs/Audit Asia/Asian_ regional_audit_2009.pdf

Brown JP, Josse RG (2002) 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:1–34

Chandran M, Tan MZW, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures - An ‘OPTIMAL’ model of care from Singapore. Osteoporosis Int 24:2809–2817

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937PubMed

Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526PubMedPubMedCentral

Klop C, Gibson-Smith D, Elders PJM, Welsing PMJ, Leufkens HGM, Harvey NC, Bijlsma JWJ, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporos Int 26:1919–1928PubMedPubMedCentral

Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA - J Am Med Assoc 302:1573–1579

10.

Ahmed L, Center J, Bjørnerem Å et al (2013) Progressively increasing fracture risk with advancing age after initial incident fragility fracture: The Tromso Study. J Bone Miner Res 28:2214–2221PubMed

11.

Merchant RA, Lui KL, Ismail NH, Wong HP, Sitoh YY (2005) The relationship between postoperative complications and outcomes after hip fracture surgery. Ann Acad Med Singapore 34:163–168PubMed

12.

Singer A, Exuzides A, Spangler L, O’Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan R (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53–62PubMed

13.

Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581–593PubMed

14.

Varacallo MA, Fox EJ (2014) Osteoporosis and its complications. Med Clin North Am 98:817–831PubMed

15.

Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35PubMed

16.

Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs - an analysis using national health databases. Osteoporos Int 24:2639–2647PubMed

17.

Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 17:43–49

18.

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMed

19.

Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968PubMed

20.

Cheen MHH, Kong MC, Zhang RF, Tee FMH, Chandran M (2012) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 23:1053–1060PubMed

21.

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis Foundation (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381PubMedPubMedCentral

22.

Centers for Disease Control and Prevention (2020) Adult body mass index. [cited 2020 Aug 3]. Available from: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html

23.

Outcomes KDIG (2012) KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf

24.

Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 22:397–403PubMedPubMedCentral

25.

Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3–12PubMed

26.

Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155PubMed

27.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMed

28.

Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172PubMed

29.

Panneman MJM, Lips P, Sen SS, Herings RMC (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124PubMed

30.

Bor A, Matuz M, Gyimesi N, Biczók Z, Soós GDP (2015) Gender inequalities in the treatment of osteoporosis. Maturitas 80:162–169PubMed

31.

Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E (2016) Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int 27:387–396PubMed

32.

Nayak S, Roberts MS, Chang CCH, Greenspan SL (2010) Health beliefs about osteoporosis and osteoporosis screening in older women and men. Health Educ J 69:267–276PubMedPubMedCentral

33.

Johnson CS, McLeod W, Kennedy L, McLeod K (2008) Osteoporosis health beliefs among younger and older men and women. Heal Educ Behav 35:721–733

34.

Marsh D, Åkesson K, Beaton D et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporosis Int 22(7):2051–2065

35.

Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390PubMedPubMedCentral

36.

Beaton DE, Dyer S, Jiang D et al (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int 25:289–296PubMed

37.

Roux C, Briot K (2020) The crisis of inadequate treatment in osteoporosis. Lancet Rheumatol 2:110–119

38.

Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52:1031–1041PubMed

39.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231PubMed

40.

Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMed

41.

Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340–347PubMedPubMedCentral

42.

Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876–883PubMedPubMedCentral

43.

Saw SM, Hong CY, Lee J, Wong ML, Chan MF, Cheng A, Leong KH (2003) Awareness and health beliefs of women towards osteoporosis. Osteoporos Int 14:595–601PubMed

44.

Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMed

45.

Chen I, Chiang C, Li Y et al (2015) Nationwide cohort study of hip fractures: time trends in the incidence rates and projections up to 2035. Osteoporosis Int 26(2):681–688

Title: Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore
Authors: Yi Ting Chau
Nazrul Nashi
Lawrence Siu-Chun Law
Raymond Kai Heng Goh
Selena Xueli Choo
Santhosh Kumar Seetharaman
Publication date: 01-12-2020
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
Osteoporosis
Denosumab
Denosumab
Published in: Archives of Osteoporosis / Issue 1/2020
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-020-00816-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

Abstract

Summary

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Adequacy of calcium intake in Spanish population according age groups

Calcium intake in an adult Ukrainian population

Teriparatide and bisphosphonate use in osteoporotic spinal fusion patients: a systematic review and meta-analysis

Does (mis)use of industrial liquid silicone implants interfere with bone mineral density in transgender women?

Estimation and projection about the standardized prevalence of osteoporosis in mainland China

Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries’ osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)